Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
Authors
Discussion
Loading...
Member takes
Implication
Randomized trial demonstrates improved progression-free survival with dual BRAF-MEK inhibition in metastatic melanoma, supporting dual-pathway blockade over monotherapy.
Key Points
- To determine whether combining dabrafenib and trametinib enhances progression-free survival compared with dabrafenib alone in untreated BRAF-mutated metastatic melanoma.
- Randomized interventional clinical trial (ClinicalTrials.gov number NCT01584648) in previously untreated patients with metastatic melanoma harboring BRAF V600E or V600K mutations.
- Assigned participants to receive either combination therapy with dabrafenib plus trametinib or monotherapy with dabrafenib alone.
- Combination therapy with dabrafenib plus trametinib improved the rate of progression-free survival relative to dabrafenib monotherapy.
- Dual targeted inhibition demonstrated superior disease control over single-agent BRAF inhibition in treatment-naive BRAF V600-mutant melanoma.
Cite This Study
Long et al. (2014) studied this question.